Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ANNX Annexon Inc

0.00 (0.00%)
Pre Market
Last Updated: 04:00:00
Delayed by 15 minutes


Draw Mode:

Volume 262
Bid Price 4.68
Ask Price 5.00
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Annexon Inc ANNX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 4.68 04:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
3 262 - 1.57 - 8.40
Last Trade Time Type Quantity Stock Price Currency
04:57:06 10 $ 4.68 USD

Annexon Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
249.16M 53.24M - 0 -134.24M -2.52 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Annexon News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ANNX Message Board. Create One! See More Posts on ANNX Message Board See More Message Board Posts

Historical ANNX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.965.184.204.561,819,999-0.28-5.65%
1 Month4.555.354.204.681,892,0320.132.86%
3 Months5.608.404.205.671,998,067-0.92-16.43%
6 Months2.578.402.275.161,477,3952.1182.10%
1 Year6.028.401.574.431,064,258-1.34-22.26%
3 Years21.9724.851.575.64581,363-17.29-78.70%
5 Years16.863538.011.577.14492,913-12.18-72.25%

Annexon Description

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.

Your Recent History

Delayed Upgrade Clock